ViroGates A/S

ViroGates A/S Working Capital

The Working Capital of ViroGates A/S (VIRO.CO) as of Nov 22, 2026 is 21.03 M DKK. In the previous year, Working Capital was 14.52 M DKK — a change of 44.85% (higher).

Working Capital

21.03 MDKK

YoY

44.85%

Last updated:

Working Capital of ViroGates A/S is 2025 21.03 M DKK. Working Capital of ViroGates A/S was 2024 14.52 M DKK. It decreases by 44.85% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ViroGates A/S Stock analysis

What does ViroGates A/S do? ViroGates A/S develops and markets prognostic products for the healthcare sector, focusing on the suPARnostic product line that measures soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The suPARnostic Quantitative Point of Care Quick Triage test is designed for patient triage in acute care settings, while the Quantitative ELISA Assay targets clinical routine use. Healthcare providers, including hospitals and clinics, purchase these products to assess immune activation levels and monitor disease progression, particularly for conditions like HIV-1-infection, malaria, tuberculosis, and sepsis. The company generates revenue through the sale of these diagnostic tools to healthcare institutions for use in patient care and disease management. The suPARnostic product line serves as a marker for survival chances upon hospital admission and aids in early intervention by detecting elevated suPAR levels linked to increased inflammation and mortality risk. High suPAR levels are associated with infectious diseases such as Streptococcus pneumonia bacteraemia, pneumococcal pneumonia, and bacterial and viral CNS infections. Healthcare facilities utilize the quantitative tests to determine patient prognosis and guide treatment decisions, ensuring timely interventions that improve patient outcomes. ViroGates A/S monetizes its diagnostic solutions by supplying healthcare systems with tools that enhance clinical decision-making and patient monitoring capabilities. ViroGates A/S targets healthcare providers who require rapid and accurate diagnostic tools for acute care and routine clinical use. The company's products are specifically tailored for monitoring immune activation in patients with infectious diseases, offering both point-of-care testing and laboratory-based assays. By providing these specialized diagnostic solutions, ViroGates A/S supports healthcare institutions in managing patient care more effectively, leading to better health outcomes and reduced mortality rates. Revenue is derived from the direct sale of suPARnostic tests to hospitals, clinics, and other clinical facilities that integrate these tools into their diagnostic workflows. ViroGates A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ViroGates A/S stock

Working Capital of ViroGates A/S is 21.03 M DKK in 2025.

Working Capital of ViroGates A/S changed from 14.52 M DKK to 21.03 M DKK, representing a 44.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Working Capital ViroGates A/S since 2006 – with annual values, charts, and detailed analysis.

Working capital is the difference between current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations.

Working Capital's DKK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Working Capital's ViroGates A/S historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ViroGates A/S

All Key Metrics — ViroGates A/S